AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04376450 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Experimental- Nonincised papillae surgical approach
Description: The basic principle of the technique is the placement of only one buccal horizontal or oblique incision in the mucosa, as apically as possible from the periodontal defect and the marginal tissues, and the raising of a mucoperiosteal flap coronally, which permits apical access to the defect but leaving the marginal tissues intact, acting as a dome for the protection of the clot.
Study NCT04376450 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Active comparator- Entire papilla preservation technique
Description: The entire Papilla Preservation Technique is to preserve the whole integrity of the defect- associated papilla providing a tunnel-like undermining incision. The completely preserved interdental papilla provides an intact gingival chamber to stabilize the blood clot and improve the wound healing process. To provide adequate access for debridement, EPP requires a short buccal vertical releasing incision on the buccal side of the neighboring tooth extending just beyond the mucogingival line.
Study NCT02674945 — intervention group
Intervention type: DEVICE
Intervention: Wireless Activity tracker: Fitbit
Description: Patients will wear a Fitbit flex
Study NCT00629395 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Captain's Log Computer Program
Description: 12 Computer Program
Study NCT03437447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisticid
Description: Participants received single oral dose of 1200 mg (two 600 mg tablets) Cisticid (Test) on Day 1 (Treatment Period 1) or Day 8 (Treatment Period 2) or Day 15 (Treatment Period 3).
Study NCT03437447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biltricide
Description: Participants received 600 mg of Biltricide (Reference) tablet at a dose of 1200 mg on either Day 1 (Treatment Period 1) or Day 8 (Treatment Period 2).
Study NCT03778437 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: subclavian vein catheterization
Description: Here we introduced a new freehand method, named as Aiming Method, which facilitated the alignment of injection needles with ultrasound beams. During this aiming method, patient is still positioned in Tredelenburg with the arm abducted to 90° and no needle guidance will be used.
Study NCT03778437 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: landmark techniques
Description: The patient is positioned in Tredelenburg with the arm abducted to 90°. Venipuncture should occur 1 cm lateral to the curvature of the middle third of the clavicle with the needle pointing horizontally directed at the sternal notch. If subclavian vein is missing at the first try, withdraw the needle and direct horizontally at the cricoid cartilage at the second try.
Study NCT03778437 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided plus needle guide techniques
Description: Subclavian vein catheterization is performed under ultrasound guidance with in-plane technique. The patient is positioned in Tredelenburg with the arm abducted to 90°. During the needle insertion, the needle is secured in the needle guidance device which keeps the alignment of needle and ultrasonic beam.
Study NCT03069586 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary recruitment
Description: At the end of surgery a manual pulmonary recruitment (5 sec, max 40 cmH2O) is given to the patiënt
Study NCT02713451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modulation of Inspired Fraction of Oxygen (FiO2)
Description: In the two groups, if patient is not in the range of arterial oxygen pressure (PaO2), Inspired Fraction of Oxygen (FiO2) will be modified from 5 percent if difference between target is less than 5 mmHg and from 10 percent if difference from target is higher. A new arterial blood gases (ABG) will be performed 30 minutes later to check for the oxygen target range. When ABG are performed, pulsed oxymetry is compared with arterial saturation (SaO2) to adapt survey. Between each ABG, FiO2 is modified from 5 percent to 5 percent each five minutes until reaching good pulsed oxygen saturation (SpO2) target (that can be modified in function of the comparison of arterial oxygen saturation (SaO2 and SpO2 with ABG).~This management of FiO2 will be done until extubation of the patient.
Study NCT02713451 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Modulation of Inspired Fraction of Oxygen (FiO2)
Description: In the two groups, if patient is not in the range of arterial oxygen pressure (PaO2), Inspired Fraction of Oxygen (FiO2) will be modified from 5 percent if difference between target is less than 5 mmHg and from 10 percent if difference from target is higher. A new arterial blood gases (ABG) will be performed 30 minutes later to check for the oxygen target range. When ABG are performed, pulsed oxymetry is compared with arterial saturation (SaO2) to adapt survey. Between each ABG, FiO2 is modified from 5 percent to 5 percent each five minutes until reaching good pulsed oxygen saturation (SpO2) target (that can be modified in function of the comparison of arterial oxygen saturation (SaO2 and SpO2 with ABG).~This management of FiO2 will be done until extubation of the patient.
Study NCT01322906 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Group 1
Description: Thirty of the enrolled patients were assigned to Group B to receive comprehensive treatment, as well as allogeneic bone marrow mesenchymal stem cells transplantation by peripheral vein(2×105/Kg, once a week, 4 times).
Study NCT01322906 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Group 2
Description: Thirty of the enrolled patients were assigned to Group B to receive comprehensive treatment, as well as allogeneic bone marrow mesenchymal stem cells transplantation by peripheral vein(1×106/Kg, once a week, 4 times).
Study NCT01322906 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Group 3
Description: Thirty of the enrolled patients were assigned to Group B to receive comprehensive treatment, as well as allogeneic bone marrow mesenchymal stem cells transplantation by peripheral vein(5×106/Kg, once a week, 4 times).
Study NCT02407626 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Total intravenous anesthesia is a clinical standard procedure
Study NCT02407626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: Volatile anesthesia is a clinical standard procedure
Study NCT01511445 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Anterior cervical discectomy and fusion (ACDF) with PEEK Cage
Description: Anterior cervical discectomy and fusion with the use of a PEEK plastic interbody spacer
Study NCT01511445 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anterior cervical discectomy and fusion (ACDF) with a Valeo CSC Cage
Description: Anterior cervical discectomy and fusion with a Valeo ceramic cage interbody spacer.
Study NCT00709202 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betahistine
Description: Subjects will be started on 8 mg BID of Betahistine and titrated up to 24 mg BID (BID = 2 times a day)..
Study NCT00709202 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Study NCT03069586 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: No pulmonary recruitment
Description: At the end of surgery no intervention was completed
Study NCT01681745 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryo-Touch III
Study NCT01840735 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GS-5737
Study NCT01840735 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01739101 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reproductive Life Plan
Description: A structured discussion based on the Reproductive Life plan, including information about reproduction and a brochure with the same information.
Study NCT02903004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trabectedin
Study NCT02903004 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Pegylated Liposomal Doxorubicin
Study NCT02903004 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Topotecan
Study NCT02903004 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Gemcitabine
Study NCT02903004 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Weekly Paclitaxel
Study NCT02903004 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Carboplatin
Study NCT02500537 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endo GIA™ Reinforced Reload with Tri-Staple™ Technology
Description: Endo GIA™ Reinforced Reload with Tri-Staple™ Technology (Universal Handle)
Study NCT04717206 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plyomtric training to female badmninton players
Description: Plyometric training has been proven to be effective and effecient in developing strength and speed.~plyometric training includes different types hops,jumping,drills.
Study NCT03266679 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Metacognitive Reflection and Insight Therapy - Adapted
Description: The intervention involves the following elements: setting an agenda, developing a therapeutic relationship, therapist transparency and insertion of therapist's mind, analysis of narrative episodes, problem definition, stimulating self-reflection and understanding of others, stimulating mastery, reflecting on therapeutic relationship, and client assessment of outcomes.
Study NCT05451420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PegIFN α- 2b
Description: Adjuvant immunotherapy with GM-CSF and Hepatitis B vaccine~；GM-CSF（100 μg/ piece, produced by Xiamen Tebao Bioengineering Co., Ltd）；Hepatitis B vaccine（Each 1.0ml/HBsAg60 μ g. Shenzhen Kangtai Biological Products Co., Ltd）
Study NCT05451420 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PegIFN α- 2b
Description: Adjuvant immunotherapy with GM-CSF and Hepatitis B vaccine~；GM-CSF（100 μg/ piece, produced by Xiamen Tebao Bioengineering Co., Ltd）；Hepatitis B vaccine（Each 1.0ml/HBsAg60 μ g. Shenzhen Kangtai Biological Products Co., Ltd）
Study NCT01273974 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: intradermal influenza vaccine
Description: 0.25ml ,intradermal
Study NCT01273974 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: intramuscular influenza vaccine
Description: 0.5ml,intramuscular
Study NCT03134222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanraplenib
Description: 30 mg tablets administered orally once daily with or without food
Study NCT00914693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethinylestradiol/Gestodene (BAY86-5016)
Description: 7-day patch containing 0.55 mg ethinylestradiol (EE) and 2.1 mg gestodene (GSD) in a 21-day regimen
Study NCT00284830 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implantable Pulse Generators
Description: dual-chamber minimal ventricular pacing with the use of new pacemaker features designed to promote atrioventricular conduction, preserve ventricular conduction, and prevent ventricular desynchronization
Study NCT05253456 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Derma -Dartos Flap for second layer closure
Description: usage of Derma -Dartos Flap for second layer closure of a distal penile hypospadias in circumcised patients
Study NCT02920125 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SUVED
Description: Ayurvedic formulation in ghana (concentrated) in capsules; 500 mg each
Study NCT02920125 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: REIMMUGEN
Description: Whole Cow colostrum in powder put in capsules; 300mg each
Study NCT02920125 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Grain flour placebo
Description: Grain flour in capsules. Jowari flour in dummy Reimmugen and Ragi flour in dummy Suved placebos
Study NCT03379519 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multi-domain Attention Training (MAT)
Description: The training content emphasis three concept of attention include: intensity of attention, executive attention, and spatial orienting attention.
Study NCT03379519 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Passive information activities (PIA)
Description: The active control group (Passive information activities) training content included reading online e-books and playing online games.
Study NCT00372892 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: 375mg/m2 per week for 4 consecutive weeks
Study NCT00372892 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline IV placebo once per week for 4 consecutive weeks
Study NCT00045942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Itraconazole was commercially available.
Study NCT01449890 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: E-mail follow up care
Description: After having terminated inpatient CBT patients receive follow up care by email for 12 weeks (on average one contact per week). The follow up care aims at supporting the patients in continuing exercises in order to cope with depression.
Study NCT03679403 — intervention group
Intervention type: OTHER
Intervention: Psychiatric diagnosis
Description: Kiddie Schedule for Affective Disorders \& Schizophrenia (K-SADS) for DSM-5
Study NCT00045942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PKC412
Description: PKC412 was supplied as soft gelatin capsules containing 25 mg PKC412.
Study NCT00559689 — intervention group
Intervention type: DRUG
Intervention: Budesonide,hydrofluoroalkane-beclomethasone dipropionate
Description: receive twice-daily administration
Study NCT00559689 — intervention group
Intervention type: DRUG
Intervention: Budesonide,hydrofluoroalkane-beclomethasone
Description: once-daily administration at bedtime
Study NCT04156321 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Moringa fry
Description: School Tiffin:~Each of the adolescent girls will receive fresh Moringa leaves (150 gram) cooked in a traditional manner as Sajna shak (stir-fried)/ bora with rice and concentrated dal once daily for 5 days during tiffin time. Sajna Stir fry and bora will be given on every alternative day. Standard questionnaire will be used to measure the compliance of food. As we are serving the food in school premises during tiffin period, it would be both unethical and socially unacceptable if few of the students from a section receive the meal. Therefore, all the students from selected section/sections will receive the daily meal. However, we will only collect information from the selected study participants who would give consent to participate in the study Each of the combination of tiffin meal will supply 411 calories in the both arm .
Study NCT00570245 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitric oxide
Description: inhalation, 10 ppm, for up to 48 hours
Study NCT00570245 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitric oxide
Description: inhalation; 10ppm; 3 hours (donor) up to 48 hours (recipient)
Study NCT00277758 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Interleukin 2
Description: Interleukin-2 at 1.2 mU/M2 administered subcutaneously daily
Study NCT00277758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Ribavirin @ 800 mg daily (\< 65 kg body weight), 1000 mg (65-85 kg), and 1200 mg (> 85 kg)
Study NCT03134222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgotinib
Description: 200 mg tablets administered orally once daily with or without food
Study NCT03134222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanraplenib placebo
Description: Tablets administered orally once daily with or without food
Study NCT03134222 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lanraplenib placebo
Description: Tablets administered orally once daily with or without food
Study NCT03134222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgotinib placebo
Description: Tablets administered orally once daily with or without food
Study NCT03134222 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Filgotinib placebo
Description: Tablets administered orally once daily with or without food
Study NCT00277758 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: Ribavirin @ 800 mg daily (\< 65 kg body weight), 1000 mg (65-85 kg), and 1200 mg (> 85 kg)
Study NCT00277758 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegylated Interferon Alpha
Description: Pegylated-Interferon-alpha 1.5 ug/kg weekly subcutaneously.
Study NCT03645785 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Normal fluid intake without true lemon
Description: 16.9oz water with True Lemon
Study NCT03645785 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Double fluid intake plus 3 bottles of water with True Lemon
Description: No intervention
Study NCT00322166 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sunlight
Description: Subjects in the intervention groups will be asked to undergo exposure of approximately 15% of their body (ie the face, hands and arms) usually between 9.30am - 10am daily during the year, 5 days per week.
Study NCT00322166 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sunlight and calcium
Description: Subjects in the intervention groups will be asked to undergo exposure of approximately 15% of their body (ie the face, hands and arms) usually between 9.30am - 10am daily during the year, 5 days per week. In the calcium and sunlight arm, calcium supplements (Caltrate, 600mg elemental calcium, Whitehall) will be administered to the whole group via the Blister/ Webster packs.
Study NCT00322166 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: control
Description: Subjects in the control group will be provided with a brochure about vitamin D deficiency and how to treat it. They will receive their usual routine care and nutrition.
Study NCT00520234 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Caspofungin
Description: 50 mg IV daily
Study NCT00520234 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: 100 cc IV daily
Study NCT00277758 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pegylated Interferon Alpha
Description: Pegylated-Interferon-alpha 1.5 ug/kg weekly subcutaneously.
Study NCT00277758 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inteleukin-2
Description: Interleukin-2 administered as a daily subcutaneous injection at 1.2 mU/M2 BSA
Study NCT02443961 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal Stem Cell (MSC) therapy
Description: 3 doses of 5 million MSC will be administered
Study NCT00277758 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin + Pegylated interferon-alpha
Description: Pegylated interferon-alpha administered 1.5 ug/kg weekly. Ribivirin 800 mg daily for body weight \<65 kg, 1000 mg for body weight 65-85 kg, and 1200 mg for body weight >85 kg.
Study NCT00849589 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized screening and brief physician advice
Description: Participants complete screening for alcohol use and other health risk behaviors on the computer, receive some related health information on the computer, and meet with a primary care provider for a short discussion of health risk behaviors
Study NCT00849589 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized SBA with technological extenders
Description: Participants complete screening for alcohol use and other health risk behaviors on the computer, receive some related health information on the computer, and meet with a primary care provider for a short discussion of health risk behaviors. In addition, the provider sends them a brief email or text message at 4 months and 9 months after study entry to reinforce the brief advice.
Study NCT02866422 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: Observational Study: No intervention
Study NCT00436163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a
Description: 180 mcg subcutaneously once per week for 48 weeks.
Study NCT01061281 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tecnis MF IOL
Description: 20 patients enrolled with the Tecnis MF IOL.
Study NCT01061281 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Crystalens AO IOL
Description: 20 patients enrolled with the Crystalens AO
Study NCT02620891 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: helium oxygen mixture
Study NCT00397488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib malate
Study NCT04566848 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Flow cytometric analysis
Description: Measuring the sCD25 (IL-2Ra), 4-1BB, B7.2 (CD86), Free Active TGF-β1, CTLA-4, PD-L1, PD-1, Tim-3, LAG-3, Galectin-9 levels with flow cytometry
Study NCT03193177 — intervention group
Intervention type: OTHER
Intervention: the 21-day fasting-like diet
Description: a fasting-like diet with 400 KJ energy intake per day for 21 days
Study NCT01764347 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo robotic radical prostatectomy
Study NCT01962779 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure (CPAP)
Description: Continuous positive airway pressure (CPAP). CPAP typically is used for people who have breathing problems, such as sleep apnea.